Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer's disease

Immunity and Ageing

Volumn 10, Issue 1, 2013, Pages

  Porcellini, Elisa ^a   Ianni, Manuela ^a   Carbone, Ilaria ^a   Franceschi, Massimo ^b   Licastro, Federico ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Alzheimer's disease; MCI AD conversion; MCP 1 plasma levels; MCP 1 promoter polymorphism

Indexed keywords

APOLIPOPROTEIN E4; MONOCYTE CHEMOTACTIC PROTEIN 1;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874008663     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-10-6     Document Type: Article

References (41)

1. Meda I, Baron P, Scarlato G. Glial activation in Alzheimer's disease: The role of Abeta and it's associated proteins. Neurobiol Aging 2001, 22:885-893. 10.1016/S0197-4580(01)00307-4, 11754995.
2. Breteler MMB, Claus JJ, van Duijn CM, Launer LJ, Hofman A. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992, 14:59-82.
3. Licastro F, Porcellini E, Caruso C, Lio D, Corder EH. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 2007, 28(11):1637-1643. 10.1016/j.neurobiolaging.2006.07.007, 16930778.
4. Licastro F, Porcellini E, Chiappelli M, Forti P, Buscema M, Ravaglia G, Grossi E. Multivariable network associated with cognitive decline and dementia. Neurobiol Aging 2010, 31:257-269. 10.1016/j.neurobiolaging.2008.03.019, 18485535.
5. Licastro F, Carbone I, Ianni M, Porcellini E. Gene signature in Alzheimer's disease and environmental factors: the virus chronicle. J Alzheimers Dis 2011, 27:809-817.
6. Calingasan NY, Gibson GE. Vascular endothelium is a site of free radical production and inflammation in areas of neuronal loss in thiamine-deficient brain. Ann NY Acad Sci 2000, 902:353-356.
7. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002, 23:485-508. 10.1016/S0197-4580(01)00328-1, 12009495.
8. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the lipid connection. J Neurochem 2007, 1:159-170.
9. Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, Mecocci P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 2009, 8:285-305. 10.1016/j.arr.2009.04.002, 19376275.
10. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001, 22:799-809. 10.1016/S0197-4580(01)00289-5, 11754986.
11. Porcellini E, Davis EJ, Chiappelli M, Ianni E, Di Stefano G, Forti P, Ravaglia G, Licastro F. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target. Curr Pharm Des 2008, 14:2659-2664. 10.2174/138161208786264151, 18991685.
12. Kim SM, Song J, Kim S, Han C, Park MH, Koh Y, Jo SA, Kim YY. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 2011, 12:11-51.
13. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995, 21:195-218. 10.1016/0165-0173(95)00011-9, 8866675.
14. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis 1997, 175:478-481. 10.1093/infdis/175.2.478, 9203678.
15. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 2005, 166:1475-1485. 10.1016/S0002-9440(10)62364-4, 1606401, 15855647.
16. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P. Dutch-Italian Alzheimer Research Group: Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 2003, 53:547-548. 10.1002/ana.10531, 12666129.
17. Corrêa JD, Starling D, Teixeira AL, Caramelli P, Silva TA. Chemokines in CSF of Alzheimer's disease patients. Arq Neuropsiquiatr 2011, 69:455-459. 10.1590/S0004-282X2011000400009, 21755121.
18. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012, 7:e30525. 10.1371/journal.pone.0030525, 3268759, 22303443.
19. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corrà B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging 2006, 27:1763-1768. 10.1016/j.neurobiolaging.2005.10.007, 16307829.
20. Corsi MM, Licastro F, Porcellini E, Dogliotti G, Galliera E, Lamont JL, Innocenzi PJ, Fitzgerald SP. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology 2011, 12:451-454. 10.1007/s10522-011-9335-6, 21484243.
21. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, Tiriticco M, Mariani C, Forloni G, Pettenati C, Baron P, Conti G, Bresolin N, Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 2004, 25:1169-1173. 10.1016/j.neurobiolaging.2003.11.008, 15312962.
22. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999, 259:344-348. 10.1006/bbrc.1999.0796, 10362511.
23. Jibiki T, Terai M, Shima M, Ogawa A, Hamada H, Kanazawa M, Yamamoto S, Oana S, Kohno Y. Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthritis Rheum 2001, 44:2211-2212. 10.1002/1529-0131(200109)44:9<2211::AID-ART375>3.0.CO;2-A, 11592387.
24. Aguilar F, González-Escribano MF, Sánchez-Román J, Núñez-Roldán A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 2001, 58:335-338. 10.1034/j.1399-0039.2001.580508.x, 11844145.
25. Szalai C, Duba J, Prohászka Z, Kalina A, Szabó T, Nagy B, Horváth L, Császár A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001, 158:233-239. 10.1016/S0021-9150(01)00423-3, 11500196.
26. Combarros O, Infante J, Llorca J, Berciano J. No evidence for association of the monocyte chemoattractant protein-1 (-2518) gene polymorphism and Alzheimer's disease. Neurosci Lett 2004, 360:25-28. 10.1016/j.neulet.2004.01.035, 15082170.
27. Pola R, Flex A, Gaetani E, Proia AS, Papaleo P, Di Giorgio A, Straface G, Pecorini G, Serricchio M, Pola P. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Exp Gerontol 2004, 39:1249-1252.ù. 10.1016/j.exger.2004.05.001, 15288699.
28. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging 2007, 28:1810-1820. 10.1016/j.neurobiolaging.2006.08.012, 17011077.
29. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, De Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, . European Alzheimer's Disease Initiative Investigators Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099. 10.1038/ng.439, 19734903, European Alzheimer's Disease Initiative Investigators.
30. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43:429-435. 10.1038/ng.803, 3084173, 21460840.
31. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009, 19:392-398. 10.1111/j.1750-3639.2008.00188.x, 18637012.
32. El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 2008, 29:626-632. 10.1016/j.tips.2008.08.004, 18835047.
33. Boddeke H, Biber K, De Haas A, VanWeering H, De Jong E. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007, 36:137-151. 10.1007/s12035-007-0036-8, 2039784, 17952658.
34. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194. 10.1111/j.1365-2796.2004.01388.x, 15324362.
35. Monastero R, Palmer K, Qiu C, Winblad B, Fratiglioni L. Heterogeneity in risk factors for cognitive impairment, no dementia: population-based longitudinal study from the Kungsholmen Project. Am J Geriatr Psychiatry 2007, 15:60-69. 10.1097/01.JGP.0000229667.98607.34, 17194816.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944. 10.1212/WNL.34.7.939, 6610841.
37. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R, 3rd revised ed 1987, Washington DC: American Psychiatric Association, American Psychiatric Association.
38. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58:1985-1992. 10.1001/archneur.58.12.1985, 11735772.
39. Ravaglia G, Forti P, Maioli F, Orlanducci P, Sacchetti L, Flisi E, Dalmonte E, Martignani A, Cucinotta D, Cavalli G. Conselice study: a population based survey of brain aging in a muncipality of the Emilia Romagna region: (A.U.S.L. Ravenna). Design and methods. Arch Gerontol Geriatr Suppl 2001, 7:313-324.
40. Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, Canal N, Griffin WS, Franceschi M. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 2000, 47:361-365. 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N, 10716256.
41. Licastro F, Pedrini S, Govoni M, Pession A, Ferri C, Annoni G, Casadei V, Veglia F, Bertolini S, Grimaldi LM. Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease. Neurosci Lett 1999, 270:129-132. 10.1016/S0304-3940(99)00468-1, 10462111.